Europe PMC

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Pandemic COVID-19, an update of current status and new therapeutic strategies.

Author information

Affiliations

  • 1. Pharmaceutical Department, Usl Umbria 1, Via XIV Settembre, 06132, Perugia, Italy.
      Authors
    • Vitiello A 1
    (1 author)
  • 2. Clinical Pathologist, Pathology Department, ASUR Marche, Area Vasta 1, Urbino, Italy.
      Authors
    • La Porta R 2
    (1 author)
  • 3. Directorate General for Healthcare and Coordination of the Regional Healthcare System, Naples, Italy.
      Authors
    • Trama U 3
    (1 author)
  • 4. Pharmaceutical Department, Asl Napoli 3 Sud, Via Dell'amicizia 22, 80035, Naples, Nola, Italy.
      Authors
    • Ferrara F 4
    (1 author)
  • 5. Ministry of Health, Viale Giorgio Ribotta 5, 00144, Rome, Italy.
      Authors
    • Zovi A 5
    (1 author)
    • Show all (6)

ORCIDs linked to this article

Naunyn-schmiedeberg's Archives of Pharmacology, 02 Jul 2022, 395(10):1159-1165
https://doi.org/10.1007/s00210-022-02265-9 PMID: 35779085 

Review

Abstract 

The global COVID-19 pandemic is underway. In recent weeks, several countries throughout the globe, and particularly in Europe, have experienced an exponential increase in the number of individuals infected with COVID-19, probably induced by a new variant of SARS-CoV-2, called the "Omicron variant." Mass vaccination against COVID-19 continues worldwide. Are authorized mRNA vaccines effective against the new Omicron variant? Recently, several pharmaceutical companies have developed oral antiviral pills against SARS-CoV-2, i.e., molnupiravir and paxlovid, that inhibit SARS-CoV-2 viral replication by acting on the RNA polymerase of SARS-CoV. In pre-registration clinical trials, molnupiravir and paxlovid have shown excellent clinical efficacy results, but what impact will these new oral antiviral agents have against pandemic COVID-19? In what specific clinical situations are they preferred over other antivirals such as remdesivir? In this brief review, we explore these important aspects.

Full text links 

Read article at publisher's site: https://doi.org/10.1007/s00210-022-02265-9

Read article for free, from open access legal sources, via Unpaywall: https://link.springer.com/content/pdf/10.1007/s00210-022-02265-9.pdfUnpaywall

References 

Articles referenced by this article (10)

Citations & impact 

Impact metrics

9
Citations
Jump to Citations

Citations of article over time

Alternative metrics

Altmetric item for https://www.altmetric.com/details/135959339
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/135959339

Article citations

Go to all (9) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.